The Impact of Letrozole on Oocyte Quality in Assisted Reproductive Technology (Art); a Randomized Double-Blind Clinical Trial Publisher Pubmed



Hossein Rashidi B¹ ; Shahrokh Tehraninejad E¹ ; Amanpour S¹ ; Bandarian F^{2, 3} ; Bandarian M^{1, 4} Show Affiliations
Source: Gynecological Endocrinology Published:2022

Abstract

Objective: To examine the effect of letrozole on oocyte quality and pregnancy outcome in assisted reproductive technology (ART). Methods: This double blind placebo controlled clinical trial was conducted in Vali-Asr Infertility Center. Infertile women candidate for IVF that underwent antagonist protocol were selected. Eligible women randomly allocated into treatment (letrozole/Let group) and control (placebo) group. Participants received letrozole 5 mg/day or placebo at the time of gonadotropin start until trigger day in the same manner. Number of oocyte retrieved, metaphase II oocyte number, high grade oocyte number (G1), high quality embryo, Chemical and clinical pregnancy rate and OHSS (ovarian hyperstimulation syndrome) rate was recorded. 216 infertile women (104 in letrozole and 112 in the control group) were evaluated. Results: In the Let group estradiol level was significantly lower (p_value <.001) and testosterone significantly higher than in the control group (p_value =.02). The number of retrieved oocytes, MII oocytes, G1 oocytes, and 2PN was significantly lower in the Let group (p <.05). No significant difference was found in the day of stimulation, total gonadotropin dose, OHSS rate, and clinical pregnancy rate between the two groups (p > 0.05). Conclusions: According to the results, letrozole may reduce oocyte quality and cause poor IVF outcomes as well. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.